Incidence and Impact of Routine Inflammatory Parameters on Outcome after Transcatheter Aortic Valve Replacement.
Journal
Journal of interventional cardiology
ISSN: 1540-8183
Titre abrégé: J Interv Cardiol
Pays: United States
ID NLM: 8907826
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
11
2020
revised:
13
03
2021
accepted:
26
03
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
9
7
2021
Statut:
epublish
Résumé
Previous research reported adverse clinical outcomes in association with systemic inflammation (SI) after transcatheter aortic valve replacement (TAVR). However, data characterizing the impact of SI, as reflected by postprocedural routine inflammatory parameters (pRIP), on clinical outcome of patients undergoing TAVR are sparse. In light of this, the present work aimed to analyze incidence and clinical significance of pRIP after transapical (TA) and transfemoral (TF)-TAVR. Data of 81 high-risk consecutive patients undergoing TAVR in our center from 2017 to 2018 were analyzed in a retrospective manner. 40 out of 81 patients (49, 4%) were treated via TF access (group A) and 41 patients via TA access (group B). Incidence, cause, and amplitude of pRIP were analyzed in relation to pre- and peri-interventional data. Assessment of outcomes was conducted according to the valve academic research consortium (VARC-2). Postprocedural C-reactive protein (pCRP) and leucocytes (pL) were significantly increased in patients undergoing TA-TAVR (group B) vs. TF-TAVR (group A; 12.1 ± 9.7 vs. 22.1 ± 7.9 mg/dl, pRIP are significantly increased in patients undergoing TA-TAVR. pCRP >30 mg/dl, ES>20%, and pL > 14/nl are hallmark of adverse prognosis and require further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
Previous research reported adverse clinical outcomes in association with systemic inflammation (SI) after transcatheter aortic valve replacement (TAVR). However, data characterizing the impact of SI, as reflected by postprocedural routine inflammatory parameters (pRIP), on clinical outcome of patients undergoing TAVR are sparse.
OBJECTIVES
OBJECTIVE
In light of this, the present work aimed to analyze incidence and clinical significance of pRIP after transapical (TA) and transfemoral (TF)-TAVR.
METHODS AND RESULTS
RESULTS
Data of 81 high-risk consecutive patients undergoing TAVR in our center from 2017 to 2018 were analyzed in a retrospective manner. 40 out of 81 patients (49, 4%) were treated via TF access (group A) and 41 patients via TA access (group B). Incidence, cause, and amplitude of pRIP were analyzed in relation to pre- and peri-interventional data. Assessment of outcomes was conducted according to the valve academic research consortium (VARC-2). Postprocedural C-reactive protein (pCRP) and leucocytes (pL) were significantly increased in patients undergoing TA-TAVR (group B) vs. TF-TAVR (group A; 12.1 ± 9.7 vs. 22.1 ± 7.9 mg/dl,
CONCLUSION
CONCLUSIONS
pRIP are significantly increased in patients undergoing TA-TAVR. pCRP >30 mg/dl, ES>20%, and pL > 14/nl are hallmark of adverse prognosis and require further investigation.
Identifiants
pubmed: 33935600
doi: 10.1155/2021/6628405
pmc: PMC8062171
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6628405Informations de copyright
Copyright © 2021 Polykarpos C Patsalis et al.
Déclaration de conflit d'intérêts
P. C. Patsalis is a proctor for Edwards Lifesciences. The other authors report no conflicts of interest..
Références
JACC Cardiovasc Interv. 2018 Oct 8;11(19):1956-1965
pubmed: 30219324
Eur Heart J. 2008 Jun;29(11):1463-70
pubmed: 18474941
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
JACC Cardiovasc Interv. 2013 Sep;6(9):965-71
pubmed: 24050862
N Engl J Med. 2012 May 3;366(18):1696-704
pubmed: 22443478
Circulation. 2011 Jan 25;123(3):299-308
pubmed: 21220731
J Am Coll Cardiol. 2012 Mar 27;59(13):1134-41
pubmed: 22440213
Eur Heart J. 2012 Jun;33(12):1459-68
pubmed: 22285582
J Geriatr Cardiol. 2016 Jan;13(1):31-6
pubmed: 26918010
J Am Coll Cardiol. 2012 Oct 9;60(15):1438-54
pubmed: 23036636
Circulation. 2007 Aug 14;116(7):755-63
pubmed: 17646579
N Engl J Med. 2012 May 3;366(18):1686-95
pubmed: 22443479
Am J Cardiol. 2014 Mar 15;113(6):1001-5
pubmed: 24462066
EuroIntervention. 2013 Dec;9(8):929-35
pubmed: 24035884
EuroIntervention. 2013 Apr 22;8(12):1398-406
pubmed: 23256946